|Videos|May 30, 2023
CAR-T Cell Therapies Entering the Mainstream of Cancer Clinical Trials & Treatment
Author(s)Medidata
KEY LEARNING OBJECTIVES
- Audience will have an understanding how Medidata can have an impact with Clinical Trial pharma and bio tech firms that are working in this therapeutic area
- What are the challenges that CAR-T developers face and how can data help address those challenges
- How is Medidata AI “data” different from other data providers
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Gilead’s ARTISTRY-2 Trial Shows Bictegravir Lenacapavir Combo Matches Biktarvy in Virologically Suppressed Adults With HIV
2
ACT Brief: AI-Enabled End-to-End Trials, New Phase III Data in HIV, and a First-Line Shift in HER2-Positive Breast Cancer
3
Preparing for End-to-End AI-Enabled Clinical Trials
4
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
